Biology Reference
In-Depth Information
[2] Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al.
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic
stem cell transplantation. Blood 2003;102(2):756-62.
[3] Pasquini MC. Impact of graft-versus-host disease on survival. Best Pract Res Clin Hae-
matol 2008;21(2):193-204.
[4] Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, et al. Elafin is a bio-
marker of graft-versus-host disease of the skin. Sci Transl Med 2010;2(13):13ra2.
[5] Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, et al. Regenerating
islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood
2011;118(25):6702-8.
[6] Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker
panel for acute graft-versus-host disease. Blood 2009;113(2):273-8.
[7] Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M, et al. Proteomic
patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell
transplantation. Blood 2007;109(12):5511-9.
[8] Landfried K, Zhu W, Waldhier MC, Schulz U, Ammer J, Holler B, et al. Tryptophan catab-
olism is associated with acute GVHD after human allogeneic stem cell transplantation
and indicates activation of indoleamine 2,3-dioxygenase. Blood 2011;118(26):6971-4.
[9] Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet
2009;373(9674):1550-61.
[10] Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance main-
tained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of
a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol
1995;155(3):1151-64.
[11] Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+
natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol
Rev 2006;212:8-27.
[12] Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, et al. CD4+ T-
regulatory cells: toward therapy for human diseases. Immunol Rev 2008;223:391-421.
[13] Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) im-
munoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med
2002;196(3):401-6.
[14] Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+)
regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone
marrow transplantation. J Exp Med 2002;196(3):389-99.
[15] Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)
CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood
2002;99(10):3493-9.
[16] Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+
regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host
disease after bone marrow transplantation. Nat Med 2003;9(9):1144-50.
[17] Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-
type specific CD4+CD25+ regulatory T cells favor immune reconstitution and con-
trol graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest
2003;112(11):1688-96.
[18] Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, et al. Isolation of
CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant
2006;12(3):267-74.
[19] Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent
GVHD and promote immune reconstitution in HLA-haploidentical transplantation.
Blood 2011;117(14):3921-8.
[20] Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion
of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood:
safety profile and detection kinetics. Blood 2011;117(3):1061-70.
[21] Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale
in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood
2004;104(3):895-903.
[22] Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, et al. Massive
ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of
in vivo functional activity. Sci Transl Med 2011;3(83): ra4183.
[23] Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, et al. Generation and
large-scale expansion of human inducible regulatory T cells that suppress graft-versus-
host disease. Am J Transplant 2011;11(6):1148-57.
[24] Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea 3rd EP, et al. In-
terleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med
2011;365(22):2055-66.
505
Search WWH ::
Custom Search